FIELD: biotechnology.
SUBSTANCE: group of inventions relates to an immunogen for use in preventing or treating familial frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) and/or ALS-FTD in patients with repeat expansion C9orph72. Immunogen includes a polypeptide consisting of dipeptide repeats with the sequence (Gly-Ala)a, where a is integer from 7 to 15, and an immunogenic carrier protein. Immunogenic carrier protein can be selected from tetanus toxoid (AC), HSP60, hemocyanin Concholepas (CCH), diphtheria toxin CRM197, diphtheria toxoid (AD), meningococcal outer membrane protein complex (OMPC), ovalbumin (OVA), fissurella hemocyanin (KLH) or bovine serum albumin (BSA).
EFFECT: vaccination against (Gly-Ala) leads to high titre of antibodies in plasma and significant titres in CSF and treatment of patients carrying C9orph72 mutation and suffering ALS, LVD or ALS-LVD.
16 cl, 10 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANIMALS OTHER THAN HUMANS CHARACTERIZED IN EXPANSION OF HEXANUCLEOTIDE REPEATS AT LOCUS C9orf72 | 2017 |
|
RU2760877C2 |
| VECTOR, CO-EXPRESSING MOLECULES FOR VACCINATION AND COSTIMULATORY MOLECULES | 2016 |
|
RU2714157C2 |
| VACCINATION USING THE ALPHA 3 DOMAIN OF MICA/B FOR CANCER TREATMENT | 2016 |
|
RU2747296C2 |
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2721274C2 |
| VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT USING RECOMBINANT MVA AND ANTIBODIES INTRODUCED INTRAVENOUSLY | 2018 |
|
RU2795103C2 |
| COMPOSITIONS AND METHODS FOR MODULATING THE TRANSMISSION OF A LAIR SIGNAL | 2017 |
|
RU2757394C2 |
| PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY | 2008 |
|
RU2523894C2 |
| METHODS AND COMPOSITION FOR INHIBITION OF HIV-1 MULTIPLICATION | 2001 |
|
RU2275379C2 |
| NON-HUMAN ANIMALS WITH DISTURBANCE IN LOCUS C9ORF72 | 2016 |
|
RU2725737C2 |
